Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
Anne M. Connolly(Washington University in St. Louis), Ewa Carrier(FibroGen (United States)), John F. Brandsema, Mark D. Eisner(Royal Victoria Infirmary), Craig M. Zaidman(Washington University in St. Louis), Xueping Zhang(Changchun Institute of Applied Chemistry), Cuixia Tian(Cincinnati Children's Hospital Medical Center), H. Phan(Rare Disease Therapeutics (United States)), Jack Li(FibroGen (United States))
Cited by 24
Related Papers
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2010|986
Pulmonary Dead-Space Fraction as a Risk Factor for Death in the Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2002|898
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*
|Critical Care Medicine|2005|729
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
|Annals of Internal Medicine|2011|550